Literature DB >> 12212986

Weakness of respiratory and skeletal muscles after a short course of steroids in patients with acute lung rejection.

S Nava1, C Fracchia, G Callegari, N Ambrosino, N Barbarito, G Felicetti.   

Abstract

There have been occasional reports of acute respiratory and skeletal muscle weakness in intensive care unit patients treated with massive doses of corticosteroids. However, in this setting the concomitant use of other drugs may have influenced the finding. In this study the effects of 5 days of treatment with high doses of steroids in consecutive patients with acute lung rejection after transplantation were systematically evaluated. Maximal inspiratory pressure during phrenic nerve stimulation and peak torque of isokinetic contraction of the quadriceps and hamstring muscles were measured objectively. Compared to the pretreatment condition, approximately 45% of patients showed acute generalised muscle weakness that recovered after approximately 2 months. This demonstrates muscle weakness induced by steroids within patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212986     DOI: 10.1183/09031936.02.01732002

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  12 in total

1.  Rhabdomyolysis After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Q Jiang; B H Zhang
Journal:  Indian J Hematol Blood Transfus       Date:  2016-06-09       Impact factor: 0.900

2.  Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.

Authors:  D S Hui; G M Joynt; K T Wong; C D Gomersall; T S Li; G Antonio; F W Ko; M C Chan; D P Chan; M W Tong; T H Rainer; A T Ahuja; C S Cockram; J J Y Sung
Journal:  Thorax       Date:  2005-05       Impact factor: 9.139

3.  Preferential reduction of quadriceps over respiratory muscle strength and bulk after lung transplantation for cystic fibrosis.

Authors:  C Pinet; P Scillia; M Cassart; M Lamotte; C Knoop; C Mélot; M Estenne
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

Review 4.  Bench-to-bedside review: Diaphragm muscle function in disuse and acute high-dose corticosteroid treatment.

Authors:  Catherine Sh Sassoon; Vincent J Caiozzo
Journal:  Crit Care       Date:  2009-09-08       Impact factor: 9.097

Review 5.  Early exercise rehabilitation of muscle weakness in acute respiratory failure patients.

Authors:  Michael J Berry; Peter E Morris
Journal:  Exerc Sport Sci Rev       Date:  2013-10       Impact factor: 6.230

6.  Fatal toxic myopathy attributed to propofol, methylprednisolone, and cyclosporine after prior exposure to colchicine and simvastatin.

Authors:  Lisa Francis; Eduardo Bonilla; Ekaterina Soforo; Hom Neupane; Hassan Nakhla; Christine Fuller; Andras Perl
Journal:  Clin Rheumatol       Date:  2007-07-13       Impact factor: 2.980

Review 7.  Falls in patients with chronic obstructive pulmonary disease: a call for further research.

Authors:  Marc Roig; Janice J Eng; Jeremy D Road; W Darlene Reid
Journal:  Respir Med       Date:  2009-05-05       Impact factor: 3.415

8.  Neuromuscular electrical stimulation improves exercise tolerance in chronic obstructive pulmonary disease patients with better preserved fat-free mass.

Authors:  Lara Maris Nápolis; Simone Dal Corso; José Alberto Neder; Carla Malaguti; Ana Cristina Oliveira Gimenes; Luiz Eduardo Nery
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Cardiopulmonary exercise testing in lung transplantation: a review.

Authors:  Katherine A Dudley; Souheil El-Chemaly
Journal:  Pulm Med       Date:  2012-05-14

10.  Relationship between corticosteroid dose and declines in physical function among allogeneic hematopoietic stem cell transplantation patients.

Authors:  Shinichiro Morishita; Katsuji Kaida; Shinya Yamauchi; Koichiro Sota; Shinichi Ishii; Kazuhiro Ikegame; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2013-03-09       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.